CLINICAL TRIALS PROFILE FOR OLUMIANT
✉ Email this page to a colleague
All Clinical Trials for OLUMIANT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03921554 ↗ | JAK Inhibitor Treatment in AGS | Active, not recruiting | Eli Lilly and Company | Phase 2 | 2019-06-03 | The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production |
NCT03921554 ↗ | JAK Inhibitor Treatment in AGS | Active, not recruiting | Adeline Vanderver, MD | Phase 2 | 2019-06-03 | The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production |
NCT04131738 ↗ | Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation | Recruiting | Washington University School of Medicine | Phase 1 | 2020-04-07 | In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL). Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2 inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease (aGVHD). |
NCT04345289 ↗ | Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia | Not yet recruiting | Thomas Benfield | Phase 3 | 2020-04-20 | CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled, multi-stage trial, which aims to assess the safety and efficacy of novel treatment option of moderate-severe COVID-19. Participants will be randomized 1:1:1:1:1:1 to parallel treatment arms: Convalescent plasma, sarilumab, hydroxychloroquine, baricitinib, intravenous and subcutaneous placebo, or oral placebo. Primary outcome is a composite endpoint of all-cause mortality or need of invasive mechanical ventilation up to 28 days. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OLUMIANT
Condition Name
Clinical Trial Locations for OLUMIANT
Trials by Country
Clinical Trial Progress for OLUMIANT
Clinical Trial Phase
Clinical Trial Sponsors for OLUMIANT
Sponsor Name